Kidney Disease News and Research

RSS

ASN joins ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies and Consumer Reports in the Choosing Wisely campaign. This campaign will help physicians, patients and other health care professionals address overuse of health care resources in the United States.

15 Dec 2011

Researchers uncover important source of inflammation for CKD

UC Irvine researchers have uncovered an important source of inflammation seen in people with chronic kidney disease, which is increasingly common due to the epidemic of obesity-related diabetes and hypertension.

14 Dec 2011

Unexplained kidney disease affecting rural workers across Central America, PRI's 'The World' reports

PRI's "The World" reports on an epidemic of an unexplained kidney disease that is affecting rural workers across Central America, writing, "[I]t's the second biggest cause of death among men in El Salvador, and in Nicaragua it's a bigger killer of men than HIV and diabetes combined," and "the latest theory is that the victims are literally working themselves to death."

14 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

Burned military casualties with AKI may have adverse outcomes

Acute kidney injury (AKI), an abrupt or rapid decline in kidney function, is a serious and increasingly prevalent condition. Little information has been available about how common or how severe AKI is in military personnel who are injured during combat in Iraq and Afghanistan. A new study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN) investigates this question in those burned during combat.

12 Dec 2011

ACE inhibitors, ARBs have different effects on heart health of dialysis patients

Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Most patients with AKI do not see kidney specialists within a year

Most patients with an abrupt kidney injury that does not get better do not see a kidney specialist within a year, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

FDA advisory panel OKs anemia drug peginesatide

Once approved by the FDA, the once-monthly injection could capture a share of the $3 billion U.S. market for anemia drugs used for kidney dialysis patients, currently dominated by Amgen Inc's blockbuster Epogen. Affymax, which developed the drug with partner Takeda Pharmaceutical Co Ltd, is also expected to price its product below Epogen.

8 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

Racial differences in inflammation might explain survival paradox among dialysis patients

In the general population, African Americans die at earlier ages than whites, but among patients on dialysis, African Americans live longer than whites. A new study helps explain this paradox and could help prolong the lives of all patients on dialysis.

7 Dec 2011

Relaxin improves poor blood flow and kidney function in a rat model of PKD

After a four-week course of the vasodilator hormone relaxin, kidney function and blood flow immediately improved in lab rats genetically altered to model polycystic kidney disease (PKD), a life-threatening genetic disorder, according to research presented on Dec. 6 at the American Society for Cell Biology Annual Meeting in Denver.

7 Dec 2011

FDA modifies requirements of Amgen's Nplate REMS Program

Amgen today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program.

7 Dec 2011

Mayo Clinic in Florida now offers kidney and pancreas transplants for HIV-positive patients

Mayo Clinic in Florida is now offering kidney and pancreas transplants to HIV positive patients with advanced kidney disease and diabetes. Evidence is now solid that HIV-positive patients have the same favorable outcome in terms of patient and allograft survival as non-HIV positive organ transplant recipients, says Mary Prendergast, M.D., a kidney specialist whose focus is the care of patients who receive kidney and pancreas transplants.

7 Dec 2011

Researchers reveal how podocytes may regenerate themselves during normal kidney function

Damage to podocytes -- a specialized type of epithelial cell in the kidney -- occurs in more than 90 percent of all chronic kidney disease. Now researchers at the Stanford University School of Medicine have uncovered an unexpected pathway that reveals for the first time how these cells may regenerate and renew themselves during normal kidney function.

6 Dec 2011

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).

5 Dec 2011

Potential test to diagnose membranous nephropathy in early stages

Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.

1 Dec 2011

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Study evaluates safety and effectiveness of Diamondback device for heart attacks

Drilling through concrete to create an opening may sound more like construction than medicine, but the approach is similar to what researchers at Orlando Regional Medical Center (ORMC) are doing in a clinical trial to evaluate a device that breaks through hardened coronary arteries, in an effort to prevent heart attacks and relieve chest pain.

23 Nov 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011